Definitive Healthcare Corp. SEC Filings

Stephenson Scott G reported acquisition or exercise transactions in this Form 4 filing.

Definitive Healthcare Corp. reported that director Scott G. Stephenson received a grant of 189,190 shares of Class A Common Stock in the form of restricted stock units. Each RSU represents a contingent right to one share and will vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting, subject to his continued service. Following this award, Stephenson directly holds 313,314 shares of Class A Common Stock.

Winters Kathleen A reported acquisition or exercise transactions in this Form 4 filing.

Definitive Healthcare Corp. reported that director Kathleen A. Winters received a grant of 189,190 restricted stock units (RSUs) of Class A Common Stock. The award carries no purchase price and increases her direct holdings to 308,982 shares. These RSUs vest on the earlier of June 4, 2027 or the company’s next annual meeting of stockholders, assuming she continues in service until that vesting date. This is a compensation-related equity grant rather than an open-market transaction.

Chilukuri Sastry reported acquisition or exercise transactions in this Form 4 filing.

Definitive Healthcare Corp. director Chilukuri Sastry received an equity grant of 189,190 shares of Class A Common Stock in the form of restricted stock units. These RSUs carry no purchase price and increase his direct holdings to 315,984 shares after the award.

Each RSU represents a contingent right to receive one share of Class A Common Stock. The units vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting, conditioned on his continued service through the vesting date.

Definitive Healthcare Corp. reported the results of its 2026 annual meeting of stockholders. Shareholders elected three Class II directors to terms running until the 2029 annual meeting, with each nominee receiving over 114 million votes in favor and sizable broker non-votes.

Stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 130,745,809 votes for and limited opposition. They also approved increasing the shares authorized under the 2021 Equity Incentive Plan by 15,000,000, taking the plan reserve from 30,972,789 to 45,972,789, and supported, on a non-binding advisory basis, the compensation of named executive officers.

Definitive Healthcare Corp.'s Chief Financial Officer Casey Heller reported a routine share disposition tied to taxes rather than a market trade. The company withheld 164,377 shares of Class A common stock at an effective value of $0.99 per share to cover Heller's tax obligations from vesting restricted stock units. After this tax-withholding transaction, Heller directly holds 1,841,476 shares of Class A common stock, indicating a substantial remaining equity position in the company.

Definitive Healthcare Corp. reported that CEO Kevin Coop had shares withheld to cover taxes tied to restricted stock units vesting. The Form 4 shows a tax-withholding disposition of 66,050 shares of Class A Common Stock at $0.99 per share, with no open-market trade. After this transaction, Coop is reported as directly owning 5,012,822 Class A shares, so the withheld amount is a small portion of his overall holdings and reflects a compensation-related event rather than a discretionary stock sale.

Advent International entities reported beneficial ownership of Class A common stock of Definitive Healthcare Corp. The filing lists 62,493,676 shares under shared voting and dispositive power, representing 59.82% of Class A common stock based on 104,472,371 shares outstanding as of February 23, 2026. The statement is a joint Schedule 13G/A filing that identifies the specific Advent funds and related entities holding the shares and clarifies control relationships among the Advent reporting persons.

Definitive Healthcare Corp. reported a sharp net loss as it fully wrote off goodwill and faced softer demand. For the quarter ended March 31, 2026, revenue was $55.9 million, down from $59.2 million a year earlier, with subscription services contributing $53.6 million.

The company recorded a non‑cash goodwill impairment charge of $197.2 million, eliminating its remaining goodwill and driving a net loss of $192.4 million and a basic and diluted loss per share of $1.32. Operating cash flow remained positive at $11.6 million, and cash and cash equivalents totaled $157.6 million with short‑term investments of $20.4 million.

Management cited past sales execution challenges, macroeconomic pressure on smaller and life sciences customers, and elevated churn, which reduced the customer base to about 2,260 and Enterprise Customers to 495. The company also initiated a 2026 restructuring plan, cutting roughly 40 employees and recording $1.1 million in related charges to support margin improvement.

Definitive Healthcare Corp. reported Q1 2026 results with revenue of $55.9 million, down 6% from $59.2 million in Q1 2025. The company recorded a large GAAP net loss of $192.4 million, driven by $197.2 million of goodwill impairment, but generated positive non-GAAP profitability and cash flow.

Adjusted Net Income rose to $8.5 million and Adjusted EBITDA increased to $15.3 million, or 27% of revenue. Operating cash flow was $11.6 million and Unlevered Free Cash Flow was $18.0 million. Management highlighted performance at or above the high end of guidance and noted improving retention.

For full year 2026, the company expects revenue of $220.0–$226.0 million, Adjusted EBITDA of $55.0–$59.0 million (25%–26% margin), and Adjusted Net Income of $23.0–$27.0 million.